Navigation Links
Bone Density Recovers After Teens Stop Injected Contraceptive

pporting a study to address this issue.

The researchers measured the participants?bone mineral densities when the study began, and every six months thereafter for the next two to three years. During the course of the study, 61 women stopped using the contraceptive.

The researchers found that DMPA users had a greater reduction in bone density findings than did non-users.

Dr. Scholes explained that these bone density losses seen among the DMPA users occurred at a pace similar to those experienced by women progressing through menopause.

Once the women stopped using DMPA, they experienced significant gains in bone density. The study authors wrote that the increase in bone mineral density after discontinuation of DMPA is similar to the bone mineral density increase after a woman stops breast feeding.

“The potential loss of bone density is one consideration of the many that go into a woman’s choice of contraceptive method,?Dr. Scholes said.

The researchers wrote that it is impossible to know what the women’s bone density would have been if they had never taken the drug. They added, however, that 12 months after these women stopped using DMPA, their average bone mineral density scores were “at least as high as those of the comparison women at all of the anatomical sites.?/p>

The current study was conducted to follow up an earlier study of older women (18-39 years old.) That study found that the older women lost bone density while using DMPA and increased bone mass after discontinuing the contraceptive. However, the younger women in the current study both lost bone density and increased bone density more rapidly than did the older women in the previous study.

“This study provides evidence that DMPA use by adolescents adversely impacts [bone mineral density] at key anatomical sites,?the study authors wrote. “However, these results in teens and those from our previous cohort provide reassurance that bone loss is rega
'"/>

Source:NIH


Page: 1 2 3

Related biology news :

1. Youth With HIV Take More Risks After New Meds Introduced
2. After a time-shift, mixed signals from the circadian clock
3. Drug Offers Alternative to Surgical Treatment After Miscarriage
4. Menopause Symptoms May Come Back After Stopping Menopausal Hormone Therapy
5. After the yeast is gone bacteria continue to develop flavor of sparkling wine
6. Researchers Find Drug May Give Some Cardiac Protection 24 Hours After Heart Attack
7. Teens unaware of sexually transmitted diseases until they catch one, Carnegie Mellon study finds
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bone Density Recovers After Teens Stop Injected Contraceptive

(Date:11/3/2014)... that low birth weight and preterm birth are linked ... adulthood. Findings published in the American College of Rheumatology ... that low birth weight and pre-term babies were not ... as adults. , According to the ACR, 27 ... with clinical OA. Symptoms of OA range from mild ...
(Date:11/2/2014)... of a bold quest to rid the world entirely ... announced an award of US$156 million to PATH to ... new vaccines that will interrupt the cycle of malaria ... agenda. Such vaccines would ensure that parasite reintroduction is ... bed net." , This approach to developing malaria ...
(Date:11/2/2014)... into a bar and bump into a biologist . . ... some late-night nerd sketch, researchers have taken this premise and ... namely, finding meaning in the rising oceans of genomic data. ... mutations that genome-wide studies are publishing at a dizzying rate. ... the signal from the noise (and there is no shortage ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... funded by the National Institute of Allergy and Infectious ... (NIH), have engineered a powerful inhibitor of anthrax toxin ... "This novel approach to the design of anthrax antitoxin ... it may have in anthrax treatment, but also because ...
... have discovered the gene responsible for a type of ... coordination. , This is the first neurodegenerative disease shown ... spectrin which plays an important role in the maintaining ... historical implications as well--the gene was identified in an ...
... study of the travels of the malaria parasite Plasmodium ... Paris found the parasites developing in an unexpected place: ... lymph nodes almost certainly has implications for the mammalian ... Institute (HHMI) international research scholar who led the study. ...
Cached Biology News:Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3U of MN researchers identify ataxia gene 2Malaria parasites develop in lymph nodes 2Malaria parasites develop in lymph nodes 3
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... Baltimore, MD (PRWEB) November 24, 2014 ... recruiting underrepresented patient populations into clinical trials at ... Maryland. , “Continental was created with the ... trials play a fundamental role in medical advances," ... the Tuskegee syphilis experiment to the immortal cell ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... 14 Quest Diagnostics,Incorporated (NYSE: DGX ), ... services, announced that it is scheduled to speak,at ... Care Conference on,Tuesday, March 18, 2008, at the ... is scheduled to begin at,8:45 a.m. Eastern Time., ...
... a medical device company focused on developing products for,minimally ... O,Boyle, Executive Vice President and Chief Financial Officer,is scheduled ... Conference at the Loews Miami Beach Hotel in Miami ... ET., A live Web cast of the presentation ...
... Bionovo, Inc.,(Nasdaq: BNVI ) announced today the ... Directors. Mr. Drapeau has extensive financial,management experience with ... quite excited to have access to Lou,s expertise," ... is particularly well versed,in the unique financial scenarios ...
Cached Biology Technology:Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3Louis Drapeau Joins Bionovo's Board of Directors 2Louis Drapeau Joins Bionovo's Board of Directors 3
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: